ClinicalTrials.gg
RecruitingNCT06430359VARCUWICUpdated Jan 15, 2026

Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients

An observational study in Wilson Disease, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 6 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
6 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Hepatolenticular Degeneration with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Hepatolenticular Degeneration · France.

Started
2025
with 1 other
Observational
6 of 17
5 open now
Registered
15th of 17
by date
Lead sponsor
2 of 17
Hospices Civils de Lyon

Among the 17 studies in Hepatolenticular Degeneration with a site in France, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 15th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

8 of the 17 studies in Hepatolenticular Degeneration with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 6 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hepatolenticular Degeneration with a site in France, or all of them as a file.
02

Study summary

Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. Patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations.

Treatment is based either on chelating the copper accumulated in the body using D-penicillamine or Trientine or on limiting intestinal copper absorption with zinc salts.

Monitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency.

Nevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. Without this, clinical decisions are usually made based on spot urine.

There is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine.

According to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon.

The study would aim to find the period of the day best correlated with 24h urinary copper excretion

03

Conditions studied

  • Wilson Disease

Keywords

  • Wilson disease
  • urinary copper
  • chelator
04

Who can participate

Ages eligible
6 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

- Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4).
  • Age ≥ 6 years and ≤70 years.
  • Patient able to perform 24h urine.
  • Current treatment with D-Pencillamine, Trientine or Zinc.
  • Non-opposition of patient and/or legal representatives for minor patients.

Exclusion criteria

Exclusion Criteria:

  • Patients who had a change in treatment within the last 6 months before the inclusion
  • Patients who have undergone liver transplantation
  • Patients with known chronic renal failure ( \< 30 ml/min)
  • Patients on long-term diuretic or therapy
  • Persons deprived of liberty by a judicial or administrative decision
  • Patient under judicial protection, unable to express consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group 1 - DP

    Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with D-Pencillamine

    Diagnostic Test: urine and blood test

  • Group 2 - Trientine

    Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Trientine

    Diagnostic Test: urine and blood test

  • Group 3 - ZINC

    Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Zinc.

    Diagnostic Test: urine and blood test

Interventions

  • Diagnostic testurine and blood test

    3 urine collections of an 8h period. One blood sample for liver function test and copper assessment

06

What researchers measure

Primary outcomes

  1. Correlation factor

    Correlation between 24-hour urinary copper excretion and 8-hour urinary copper excretion collected between midnight and 8 am).

    Time frame: Two 24-hour urine recollection

07

Study locations

1 of 1 sites recruiting
  • Service de Gastroentérologie, Hépatologie et Nutrition Pédiatriques - Hôpital Femme Mère Enfant
    Bron, Rhone 69500, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
May 28, 2024
StartActual
Jan 10, 2025
Primary completionEst.
Feb 10, 2027
CompletionEst.
Feb 10, 2027
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06430359
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Jan 10, 2025
Primary completion
Feb 10, 2027 (estimated)
Completion
Feb 10, 2027 (estimated)
Last update
Jan 15, 2026

Study contacts

Eduardo COUCHONNAL, Dr
Contact
eduardo.couchonnal-bedoya@chu-lyon.fr
04 27 35 70 50 ext. +33
Abdelouahed BELMALIH, PhD
Contact
abdelouahed.belmalih@chu-lyon.fr
04 27 85 62 67 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion